Traitement à long terme par une enzymothérapie substitutive la vélaglucérase alfa chez des enfants atteints de la maladie de gaucher de type 1
Gregory M. Pastores(New York University), Laurie D. Smith(Children's Mercy Hospital), E. Crombez(Lexington VA Health Care System), T. Hangartnerd(Wright State University), L. Longo(University of Utah), N. Wang(Lexington VA Health Care System), Paul Harmatz(Unknown), Joel Charrow(Northwestern University), William J. Rhead(Children's Hospital of Wisconsin)
Cited by 0
Related Papers
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555
Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
|The Journal of Pediatrics|2006|364
Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease
|Journal of Medical Genetics|2015|363
Survival after Treatment with Phenylacetate and Benzoate for Urea-Cycle Disorders
|New England Journal of Medicine|2007|357
Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management
|Journal of Inherited Metabolic Disease|2011|302